This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Best-Performing ETFs of 2008

"Ultra-short" set the style in 2008 in top-performing exchange-traded funds.

Since ETFs offer lots of "inverse" funds, which rise when indices fall and vice versa, those topped the list during the dismal year that just ended. Inverse-leveraged funds, which use borrowed money to amplify gains, did even better.

Of 620 ETFs tracked by TheStreet.com Ratings for which complete 2008 returns are available, 71 managed to avoid the maelstrom that brought down many popular equity indices by 30% or more. Most of the winners were inverse funds.

An accompanying table lists top-performers in broad classifications of ETFs.

Short funds were tops among inverse and leveraged offerings, particularly technology and growth funds. Anyone tempted to join that party should look at the column of December returns. A modest upturn in the market can hit holders with depressingly quick double-digit losses.

As the Federal Reserve lowered interest rates, the few ETFs that focus on long-term Treasury bonds easily outdistanced other investments on the "long" side. The three top-performing bond ETFs in the table achieved impressive returns over one month, three months and one year.

Among non-leveraged equity funds, health and biotechnology funds dominated, confounding some experts. The top three in that area moved up smartly in December, although only one managed a positive total return for the year.

Although it lost ground during the final quarter of 2008, HOLDRs Biotech (BBH) finished the year with a net gain of 10.2%. Its top stocks include Genentech (DNA), Amgen (AMGN), Gilead Sciences (GILD) and Biogen IDEC (BIIB).
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BBH $139.92 1.01%
XBI $255.44 1.18%
TLT $122.53 0.74%
XPH $130.95 1.27%
FXF $100.46 0.37%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs